Johan Lund named PharmNovo board chair

30 January 2026

Privately-held Swedish neuropathic pain specialist PharmNovo has announced changes to its board of directors, welcoming two new members as the company prepares for its next phase of clinical development.

According to PharmNovo, the new board composition strengthens the company’s strategic capabilities ahead of Phase II development of its lead candidate, PN6047, with the new additions bringing complementary experience in drug development, clinical execution and partnering, supporting the firm’s continued progress and dialogue with potential partners.

Johan Lund (pictured above, left, with Karin Rosén) has been appointed chairman of the board and brings more than 25 years of experience as a physician-scientist and drug development executive from leading pharma companies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK